The family of gadolinium-based imaging programs consists of MS-325 (gadofosveset trisodium), which is a commercial MRA imaging agent currently marketed as Ablavar® in the US by Lantheus Medical Imaging and formerly marketed as Vasovist® in Europe and other countries by Bayer Schering Pharma. MS-325 has been approved in 38 countries. The MS-325 commercial rights for sale include European Union, Switzerland and other regions outside the US, Canada, Puerto Rico and Australia.
MS-325 is a first-in-class gadolinium-based imaging agent that binds reversibly to serum albumin. Because albumin is at a high concentration in the blood stream, MS-325 remains in circulation for an extended period of time, providing extended intravascular enhancement compared to existing extracellular MR contrast agents.
Persons interested in bidding must sign a Confidentiality Disclosure Agreement
("CDA") obtained from Finn's Office – IPSALESERVICES@FINNWARNKEGAYTON.COM
or 781-237-8840. They will then receive a bid package and access to an electronic data room.
About Joseph F. Finn, Jr., C.P.A.
Joseph F. Finn, Jr., C.P.A. is the owner of the firm, Finn, Warnke & Gayton, Certified Public Accountants of Wellesley Hills, Massachusetts. He works primarily in the area of management consulting for distressed enterprises, bankruptcy accounting and related matters, such as assignee for the benefit of creditors and liquidating agent for a corporation. He has been involved in a number of loan workouts and bankruptcy cases for thirty-five (35) years. His most recent Assignments for the Benefit of Creditors in the biotech field include Spherics, Inc., ActivBiotics, Inc. and Prospect Therapeutics, Inc.
For further information, please contact Joseph F. Finn, Jr., C.P.A. at 781-237-8840 or
IPSALESERVICES@FINNWARNKEGAYTON.COM
SOURCE Joseph F. Finn, Jr., C.P.A.
